Naples Global Advisors LLC Sells 9,959 Shares of Pfizer Inc. $PFE

Key Points

• Naples Global Advisors LLC reduced its stake in Pfizer Inc. by 8.1% during the second quarter, selling 9,959 shares and ending with 112,715 shares valued at $2.732 million.
• In the same quarter, several other hedge funds also adjusted their positions in Pfizer, with 68.36% of the stock now owned by institutional investors.
• Pfizer reported a quarterly EPS of $0.78, surpassing estimates, and has set its FY 2025 guidance between 2.900-3.100 EPS, indicating growth expectations.

Naples Global Advisors LLC trimmed its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 8.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 112,715 shares of the biopharmaceutical company's stock after selling 9,959 shares during the quarter. Naples Global Advisors LLC's holdings in Pfizer were worth $2,732,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Capital Advisory Group Advisory Services LLC increased its position in Pfizer by 2.9% in the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after buying an additional 388 shares during the last quarter. Trust Co of the South increased its position in Pfizer by 1.5% in the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock worth $712,000 after buying an additional 441 shares during the last quarter. Charter Oak Capital Management LLC increased its position in Pfizer by 4.3% in the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock worth $258,000 after buying an additional 444 shares during the last quarter. Ballentine Partners LLC increased its position in Pfizer by 0.5% in the second quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company's stock worth $2,260,000 after buying an additional 458 shares during the last quarter. Finally, Members Trust Co increased its position in Pfizer by 2.1% in the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after buying an additional 467 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 6.8%

PFE opened at $27.21 on Thursday. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The business has a 50 day simple moving average of $24.59 and a two-hundred day simple moving average of $24.14. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a market capitalization of $154.68 billion, a price-to-earnings ratio of 14.47, a PEG ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the business earned $0.60 EPS. The business's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on PFE shares. Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. UBS Group reissued a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday. Finally, Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $28.29.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.